Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Metsera Inc. stock logo
MTSR
Metsera
$52.25
-0.5%
$36.25
$12.30
$54.47
$5.49BN/A1.31 million shs2.58 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$23.75
+0.6%
$24.57
$20.92
$30.43
$135.03B0.5545.32 million shs33.32 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Metsera Inc. stock logo
MTSR
Metsera
+0.02%+46.27%+58.21%+83.67%+5,250,999,900.00%
Pfizer Inc. stock logo
PFE
Pfizer
-1.88%-2.25%-5.42%-2.41%-18.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Metsera Inc. stock logo
MTSR
Metsera
$52.25
-0.5%
$36.25
$12.30
$54.47
$5.49BN/A1.31 million shs2.58 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$23.75
+0.6%
$24.57
$20.92
$30.43
$135.03B0.5545.32 million shs33.32 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Metsera Inc. stock logo
MTSR
Metsera
+0.02%+46.27%+58.21%+83.67%+5,250,999,900.00%
Pfizer Inc. stock logo
PFE
Pfizer
-1.88%-2.25%-5.42%-2.41%-18.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Metsera Inc. stock logo
MTSR
Metsera
2.71
Moderate Buy$58.5011.96% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.39
Hold$28.1218.39% Upside

Current Analyst Ratings Breakdown

Latest MTSR and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/24/2025
Metsera Inc. stock logo
MTSR
Metsera
Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
9/24/2025
Metsera Inc. stock logo
MTSR
Metsera
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperformMarket Perform$77.00 ➝ $57.00
9/9/2025
Metsera Inc. stock logo
MTSR
Metsera
Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/9/2025
Metsera Inc. stock logo
MTSR
Metsera
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$77.00
9/3/2025
Metsera Inc. stock logo
MTSR
Metsera
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
8/28/2025
Metsera Inc. stock logo
MTSR
Metsera
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $50.00
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$25.00 ➝ $26.00
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$32.00 ➝ $33.00
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$27.00 ➝ $28.00
(Data available from 9/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/A($2.46) per shareN/A
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.12$4.30 per share5.52$15.62 per share1.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Metsera Inc. stock logo
MTSR
Metsera
-$209.13MN/A0.00N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.8812.637.840.7816.84%21.42%9.12%11/4/2025 (Estimated)

Latest MTSR and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.58$0.78+$0.20$0.51$13.43 billion$14.65 billion
7/28/2025Q2 2025
Metsera Inc. stock logo
MTSR
Metsera
N/A-$0.66N/A-$0.66N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.24%N/A91.49%16 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Metsera Inc. stock logo
MTSR
Metsera
N/A
5.26
5.26
Pfizer Inc. stock logo
PFE
Pfizer
0.65
1.16
0.85

Institutional Ownership

CompanyInstitutional Ownership
Metsera Inc. stock logo
MTSR
Metsera
N/A
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Metsera Inc. stock logo
MTSR
Metsera
N/A
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Metsera Inc. stock logo
MTSR
Metsera
81105.06 millionN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable

Recent News About These Companies

Jim Cramer Discusses Sentiment Surrounding Pfizer (PFE)
2 Top Passive Income Stocks to Buy Now
14,681 Shares in Pfizer Inc. $PFE Acquired by FCG Investment Co
Pfizer Inc. $PFE Stock Position Increased by CX Institutional
Meyer Handelman Co. Sells 11,350 Shares of Pfizer Inc. $PFE
Pfizer (NYSE:PFE) Trading Down 2% - Should You Sell?
Pfizer: Buy The Pharma Giant Following The Metsera Deal
Pfizer: Invest For The Yield, Not The Weight-Loss Drug Chase

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Metsera stock logo

Metsera NASDAQ:MTSR

$52.25 -0.26 (-0.50%)
As of 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Pfizer stock logo

Pfizer NYSE:PFE

$23.75 +0.15 (+0.64%)
Closing price 03:59 PM Eastern
Extended Trading
$23.76 +0.02 (+0.06%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.